Vaccines to combat SARS-CoV-2 infection lose their effectiveness when the virus undergoes new mutations. Here, we will help circumvent this reality by developing a prototype vaccine that has the potential to be effective in the post-Omicron era after identifying structural patterns that are repeated in all known variants of concern (and Omicron subvariants) to date. We will evaluate more than 475 fully sequenced genomes containing a total of 1,900 sequences of SARS-CoV-2 viral proteins.